Clinical trial
Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC: an Open-label, Randomized, Prospective, Multicenter Phase III Trial
NCT07509099 is registered in ClinicalTrials.gov with Ji Dongmei as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC: an Open-label, Randomized, Prospective, Multicenter Phase III Trial
- Lead sponsor
- Ji Dongmei
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- September 15, 2026
- Completion date
- September 30, 2031
- Enrollment
- 316 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.